恆瑞醫藥(01276.HK)與GSK達成重磅合作：5億美元首付款+120億美元潛在里程碑，創新藥出海再提速
格隆匯7月28日丨恆瑞醫藥(01276.HK)發佈公告，公司與GlaxoSmithKline Intellectual Property (No. 3) Limited和GlaxoSmithKline Intellectual Property (No. 4) Limited公司(以下統稱 “GSK”)達成協議，將HRS-9821項目的全球獨家權利(不包括中國大陸、中國香港、中國澳門及中國臺灣)和至多11個項目的全球獨家許可的獨家選擇權(不包括中國大陸、中國香港、中國澳門及中國臺灣)有償許可給GSK。
HRS-9821是一款潛在的同類最佳PDE3/4抑制劑，目前正處於臨牀開發階段，可用於治療慢性阻塞性肺病(COPD)，作爲輔助維持治療，無需考慮既往治療方案。該藥物已在早期臨牀和臨牀前研究中顯示出強效的PDE3和PDE4抑制作用，從而增強支氣管擴張和抗炎作用，併爲開發便捷的乾粉吸入器(DPI)製劑提供了機會。其他11個項目涉及腫瘤、呼吸、自免和炎症等多個治療領域的創新藥物，目前均處於非臨牀研究階段。恆瑞將主導這些項目的研發，最晚至完成包括海外受試者數據的Ⅰ期臨牀試驗。
GSK是一家全球性的生物製藥公司，總部位於英國倫敦，在倫敦證券交易所和紐約證券交易所上市(證券代碼：GSK)。GSK將向恆瑞支付5億美元的首付款。如果所有項目均獲得行使選擇權且所有里程碑均已實現，恆瑞將有資格獲得未來基於成功開發、註冊和銷售里程碑付款的潛在總金額約120億美元。此外，恆瑞將有權向GSK收取相應的分梯度的銷售提成(不包括中國大陸、中國香港、中國澳門及中國臺灣)。
公告表示，本協議的簽署有助於拓寬HRS-9821和多個在腫瘤、呼吸、自免和炎症等治療領域創新產品的海外市場，爲全球患者提供優質的治療選擇，也將進一步提升公司創新品牌和海外業績。公司堅持自主研發與開放合作並重，在內生髮展的基礎上加強國際合作，實現研發成果的快速轉化，藉助國際領先的合作夥伴覆蓋海外市場，加速融入全球藥物創新網絡，實現產品價值最大化，讓公司創新產品服務全球患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
